SOUTH SAN FRANCISCO, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) announced today that its partner Serono has begun enrolling patients in a Phase I study evaluating the safety and tolerability of R763, a highly potent, orally available multi-Aurora kinase inhibitor, for the treatment of patients with refractory solid tumors. Serono licensed development and commercialization rights to Rigel’s Aurora kinase inhibitor program, including R763 for cancer, in October 2005. Rigel will receive a $3 million milestone payment from Serono triggered by the initiation of the Phase I study.
